Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients

Brazilian Journal of Infectious Diseases

Volumn 20, Issue 1, 2016, Pages 41-47

  Ahmad, Nafees ^a   Javaid, Arshad ^b   Sulaiman, Syed Azhar Syed ^a   Ming, Long Chiau ^c   Ahmad, Izaz ^d   Khan, Amer Hayat ^a  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b Postgraduate Medical Institute   (Pakistan)

^c UNIVERSITY OF TASMANIA   (Australia)

^d QUAID I AZAM UNIVERSITY   (Pakistan)

Author keywords

Fluoroquinolones; MDR TB; Private; Resistance

Indexed keywords

AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ETHNICITY; FEMALE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICAL HISTORY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PAKISTAN; PREVALENCE; PRIVATE HOSPITAL; PUBLIC HOSPITAL; RURAL AREA; SCHOOL CHILD; SEX DIFFERENCE; SMOKING; TREATMENT FAILURE; URBAN AREA; ADOLESCENT; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PAKISTAN; PREVALENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84957661423     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2015.09.011     Document Type: Article

References (32)

1. Gay J., DeYoung D., Roberts G. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii. Antimicrob Agents Chemother 1984, 26:94-96.
2. Falzon D., Gandhi N., Migliori G.B., et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2013, 42:156-168.
3. Johnston J.C., Shahidi N.C., Sadatsafavi M., Fitzgerald J.M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 2009, 4:e6914.
4. Kurbatova E.V., Taylor A., Gammino V.M., et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis 2012, 92:397-403.
5. Leimane V., Riekstina V., Holtz T.H., et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005, 365:318-326.
6. World Health Organization WHO Global Tuberculosis Report 2014. WHO/HTM/TB/2014.08 2014, World Health Organization, Geneva.
7. Jabeen K., Shakoor S., Chishti S., Ayaz A., Hasan R. Fluoroquinolone-resistant Mycobacterium tuberculosis, Pakistan, 2005-2009. Emerg Infect Dis 2011, 17:566.
8. Jabeen K., Shakoor S., Malik F., Hasan R. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Pakistan 2010-2014: implications for disease control. Int J Mycobacteriol 2014, 4:47-48.
9. Rao N.A., Irfan M., Soomro M.M., Mehfooz Z. Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients. J Coll Physicians Surg Pak 2010, 20:262-265.
10. Rafiq Y., Jabeen K., Hasan R., et al. Fluoroquinolone resistance among Mycobacterium tuberculosis strains from Karachi. Pakistan: data from community-based field clinics. Antimicrob Agents Chemother 2011, 55:929-930.
11. Long R., Chong H., Hoeppner V., et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009, 48:1354-1360.
12. Devasia R.A., Blackman A., Gebretsadik T., et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009, 180:365-370.
13. Migliori G.B., Langendam M.W., D'Ambrosio L., et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J 2012, 40:814-822.
14. Uplekar M., Health FfRiC, Rangan S. Tackling TB: the search for solutions: Foundation for Research in Community Health 1996.
15. Rintiswati N., Mahendradhata Y., Subronto Y., Varkevisser C., van der Werf M. Journeys to tuberculosis treatment: a qualitative study of patients, families and communities in Jogjakarta, Indonesia. BMC Public Health 2009, 9:158.
16. Qureshi S.A., Morkve O., Mustafa T. Patient and health system delays: health-care seeking behaviour among pulmonary tuberculosis patients in Pakistan. J Pak Med Assoc 2008, 58:318-321.
17. World Health Organization Diagnostic and treatment delay in tuberculosis. An in-depth analysis of the health-seeking behaviour of patients and health system response in seven countries of the Eastern Mediterranean Region. WHO-EM/TDR/009/E 2006, WHO, Geneva, Switzerland.
18. Naqvi S., Naseer M., Kazi A., et al. Implementing a public-private mix model for tuberculosis treatment in urban Pakistan: lessons and experiences. Int J Tuberc Lung Dis 2012, 16:817-821.
19. Shah S., Sadiq H., Khalil M., et al. Do private doctors follow national guidelines for managing pulmonary tuberculosis in Pakistan?. East Mediterr Health J 2003, 9:776-788.
20. Naseer M., Khawaja A., Pethani A.S., Aleem S. How well can physicians manage tuberculosis? A public-private sector comparison from Karachi, Pakistan. BMC Health Serv Res 2013, 13:439.
21. Abdulah R. Antibiotic abuse in developing countries. Pharmaceut Reg Aff 2012, 1:e106.
22. Butt Z.A., Gilani A.H., Nanan D., Sheikh A.L., White F. Quality of pharmacies in Pakistan: a cross-sectional survey. Int J Qual Health C 2005, 17:307-313.
23. Basit A., Ahmad N., Khan A.H., et al. Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study. PLOS ONE 2014, 9:e93206.
24. Glass B.D. Counterfeit drugs and medical devices in developing countries. Res Rep Trop Med 2014, 5:11-22.
25. Wells W.A., Ge C.F., Patel N., Oh T., Gardiner E., Kimerling M.E. Size and usage patterns of private TB drug markets in the high burden countries. PLoS ONE 2011, 6:e18964.
26. Ahmed M., Fatmi Z., Ali S., Ahmed J., Ara N. Knowledge, attitude and practice of private practitioners regarding TB-DOTS in a rural district of Sindh, Pakistan. J Ayub Med Coll Abbottabad 2009, 21:28-31.
27. Udwadia Z.F., Pinto L.M., Uplekar M.W. Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades?. PLoS ONE 2010, 5:e12023.
28. Uplekar M., Juvekar S., Morankar S. Tuberculosis patients and practitioners in private clinics 1996, The Foundation for Research in Community Health, Bombay.
29. Ahmed J., Ahmed M., Laghari A., Lohana W., Ali S., Fatmi Z. Public private mix model in enhancing tuberculosis case detection in District Thatta, Sindh, Pakistan. J Pak Med Assoc 2009, 59:82-86.
30. Pethani A., Zafar M., Khan A.A., Sana U.R., Ahmed S., Fatmi Z. Engaging general practitioners in public-private mix tuberculosis DOTS program in an urban area in Pakistan need for context-specific approach. Asia Pac J Public Health 2015, 27:984-992.
31. National TB Control Program National guidelines for programmatic management of drug-resistant tuberculosis (PMDT) 2012, http://www.ntp.gov.pk/departmentDetail.php?did=18.
32. World Health Organization Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11 2014, World Health Organization, Geneva.